

Award Number: W81XWH-12-2-0057

TITLE: Phase II Clinical Trial of Intraoral Grafting of Human Tissue-Engineered Oral Mucosa

PRINCIPAL INVESTIGATOR: Stephen E. Feinberg DDS, MS, PhD

CONTRACTING ORGANIZATION: University of Michigan  
Ann Arbor, MI 48109-1274

REPORT DATE: October 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**REPORT DOCUMENTATION PAGE***Form Approved***OMB No. 0704-0188**

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE:</b> October 2016	<b>2. REPORT TYPE:</b> Annual	<b>3. DATES COVERED</b> 30Sep2015 - 29Sep2016
<b>4. TITLE AND SUBTITLE</b>  Phase II Clinical Trial of Intraoral Grafting of Human Tissue-Engineered Oral Mucosa		<b>5a. CONTRACT NUMBER</b> N/A
		<b>5b. GRANT NUMBER</b> W81XWH-12-2-0057
		<b>5c. PROGRAM ELEMENT NUMBER</b> N/A
<b>6. AUTHOR(S)</b>  Stephen E. Feinberg DDS, MS, PhD  E-Mail: sefein@med.umich.edu		<b>5d. PROJECT NUMBER</b>
		<b>5e. TASK NUMBER</b>
		<b>5f. WORK UNIT NUMBER</b>
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  University of Michigan Ann Arbor, MI 48109-1274		<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b> USAMRAA
		<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited		
<b>13. SUPPLEMENTARY NOTES</b>		

**14. ABSTRACT**

This is a randomized, parallel-group phase II study to assess the safety and efficacy for use of human EVPOME for soft tissue intraoral grafting procedures compared to the “gold standard” palatal oral mucosa (POM) graft. The study will determine differences in the primary efficacy measure of increased keratinized mucosa; secondary measures of graft contracture and Wound Healing Index; and ancillary outcome measures of tissue perfusion measured graft color and laser Doppler flowmetry, and postoperative pain. Sixty subjects, thirty subjects per treatment group, will be randomized to receive either the experimental treatment, EVPOME (Group 1), or standard of care, the palatal oral mucosa (POM) graft (Group 2). The study population will include non-smoking adults (ages 18 and older) in need of additional keratinized oral mucosa for dental rehabilitation with dental implants. This trial has started recruitment.

**15. SUBJECT TERMS**

EVOPME, Palatal Oral Mucosa (POM), Keratinized mucosa, graft contracture

**16. SECURITY CLASSIFICATION OF:**

a. REPORT  
U

b. ABSTRACT  
U

c. THIS PAGE  
U

**17. LIMITATION OF ABSTRACT**

UU

**18. NUMBER OF PAGES**

6

**19a. NAME OF RESPONSIBLE PERSON**  
USAMRMC

**19b. TELEPHONE NUMBER** *(include area code)*

## Table of Contents

Introduction .....	5
Body .....	5
Key Research Accomplishments.....	6
Reportable Outcomes .....	6
Conclusion .....	6

## Introduction

Reconstructive procedures of the oral cavity secondary to trauma fail to achieve a satisfactory aesthetic and functional outcome. A daunting challenge for reconstructive surgeons is to regenerate oral mucosa. The free mucosal graft neither reliably restores aesthetic and functional competence, nor prevents microbial infection, fluid loss, and foreign material contamination and relapse secondary to wound contracture. Oral mucosa is in limited supply for use in reconstructive procedures in the oral cavity. This is especially prevalent after large avulsed soft tissue wounds involving the mouth and lips seen in high velocity battlefield injuries (BI). The development of an oral mucosa equivalent is necessary to fulfill this clinical need. The environment of the oral cavity, a moist area laden with bacteria and lytic enzymes, is not favorable to most of the collagen-rich dermal components used in similarly designed skin equivalents. To be useful within the intricate confines of the oral cavity an oral mucosa equivalent must possess mechanical and handling characteristics as well as similar anatomy. Engineering an Ex Vivo Produced Oral Mucosa Equivalent (EVPOME) tissue will allow the reconstruction of major oral avulsion defects. These defects are seen as secondary to traumatic injuries or oncologic resection and developmental disturbances. The EVPOME will minimize patient morbidity and improve functional outcome measures. Consequently, the goal of our clinical trial is to determine efficacy of an EVPOME as a more robust therapy than palatal oral mucosa (POM) grafts.

## Body

The Statement of Work for this project included the following:

1. Obtain IRB approval for study at University of Michigan-This has been obtained (HUM00069761).
2. Obtain IND approval from the FDA-This has been obtained (IND#: 10118).
3. Obtain approval of IRB from DoD-HRPO approval has been obtained.
4. Calibration of clinical examiners-There will only be one clinical examiner in this study so no calibration with other examiners will be necessary.
5. Calibration of laser Doppler flowmetry-This has been completed.
6. Initiation of subject screening/recruitment-Screening/recruitment is ongoing.
7. Construction and certification of a new cGMP facility; Clinical Tissue Manufacturing Laboratory (CTML): This has been completed.
8. Flyers were put together to assist in subject recruitment.
9. Iwonka Eagle will be joining the team replacing Sarah Wesley as study coordinator.
10. Completion of subject screening/recruitment
  - Twenty- four subjects have been screened for the study.
  - No subjects are currently in the screening phase.
  - Eleven were screen failures, and two subjects withdrew prior to randomization

- Eleven subjects have been randomized.
  - Of the subjects randomized, five subjects have completed the study; four have been withdrawn during follow-up and thus terminated after randomization.

11. Inclusion of first subject into clinical trial. - At the time of this report six subjects have been enrolled in the control arm and five in the experimental arm.

12. Completion of clinical trial- This has not yet occurred.

13. Data evaluation from clinical trial – This has not yet occurred.

14. Submission of findings to meeting and peer reviewed journals -This has not yet occurred.

### **Key Research Accomplishments**

Five subjects have successfully completed the study. On October 14, 2015, the “Clinical Tissue Manufacturing Laboratory” (CTML) manufacturing team starting producing the EVPOME investigational product for the first experimental arm subject in the small defect study. A protocol amendment in early 2016 revised the study inclusionary and exclusionary criteria and provided recruitment materials to local dentists, resulting in an increase in the screening and enrollment numbers over the past year.

### **Reportable Outcomes**

There are no reportable outcomes at this time.

### **Conclusion**

The study team plans to continue aggressively screening subjects and hopes to maintain a consistent subject randomization to meet enrollment as soon as possible.